How Did Merck Stock Beat The Market With Slowing Sales?

Before the eighty-five percent surge, the company’s pipeline story was getting louder just as its revenue trajectory was getting quieter.

Merck (MRK) stock surged around 85% between July 2025 and July 2026, handily beating both its large-cap pharma peers and the S&P 500. Looking back, you have to ask: did management leave a trail of breadcrumbs? The answer is yes, but they weren’t where most people were looking.

Why Weren’t The Financials The Tell

Because they were pointing the other way. Heading into the surge, Merck’s top-line story was one of deceleration. As of its fiscal Q2 2025 report, trailing-twelve-month revenue growth had slowed to 1.8%, down from a three-year average of 3.7%. If you were just screening for accelerating sales, you would have clicked right past it.

What Was Management Saying Instead

They were laying out a blueprint for a completely different company. For months, on one earnings call after another, executives were painting a picture of a pipeline vast enough to dwarf the company’s existing portfolio. By early 2025, they were explicitly flagging a “potential commercial opportunity of over $50 billion” from roughly “20 promising potential new growth drivers.” By mid-year, the CEO was running “more than 80 Phase III studies.” This amounted to a specific, quantified, and repeated roadmap to a life after its blockbuster KEYTRUDA.

When Did The Blueprint Start To Look Real

In mid-2025, just before the stock began its climb. That’s when Merck announced positive top-line results from the first Phase III trials for enlicitide, its oral PCSK9 inhibitor for cholesterol. This was the first major domino to fall. It took the “$50 billion” story from a PowerPoint slide and turned it into hard, positive data for a potential blockbuster. The CEO’s confidence on the July 2025 call was palpable, noting it was one of the “proof points” that made him see the patent cliff for KEYTRUDA as “more of a hill than a cliff.”

Was Anyone Bracing For A Move

The options market seemed to be. In the weeks before the run, implied volatility for Merck stock hovered around the 70th percentile of its one-year range. That’s not a red alert, but it’s a sign that traders were pricing in a bigger-than-usual move. They just didn’t know which direction.

The central question for Merck has long been whether its pipeline could truly offset the eventual decline of its biggest drug. A recent analysis explores if Merck’s stock can outrun its pipeline challenges.

Instead of betting on Merck’s present, the market was finally buying into its second act.

And if it is exposure to healthcare as a whole you want, rather than hunting the next single name to surge, a healthcare ETF like XLV covers that single sector.

Catching The Surge Matters Less Than Keeping It

Catching a move early is a real edge; keeping the gains it produces takes a different discipline. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.